Abstract
Introduction: The FAS/FAS-Ligand-pathway has been recognized as an important mechanism to regulate cell haemostasis of immune competent cells by activation induced cell death (AICD). The expression of Fas-Ligand of tumour cells may enable them to induce apoptosis of activated T-cells wich are especially sensitive to the FAS modulated cell death. This so called tumour counterattack may also explain why tumour cells are capable to survive in the lymphatic and circulation system. Purpose: Our objective was to test the hypothesis that a gene-therapeutically controlled blocking of the AICD mechanism of the T-cells may protect them against tumour counterattack and furthermore re-establish their immune competence towards the tumour cells. Material and Methods: A FLIP transfection was carried out using co-transfection of pMCS LNGFR and pcDNA5FRT-FLIP with X-gene transfection solution. Transfected Jurkat-T-cells were separated from non-transfected cells by paramagnetic beads. FLIP-transfected Jurkat-T-cells and SW620-colon carcinoma cells were co-incubated over 24 h. T-cell survival was shown in a fluorescence reader (Genios, Tecan) by Resazurin-converting vital cells (Celltiter Blue, Promega). The apoptosis rate was quantified by a caspase activity assay (APO-ONE, Promega) and qualified by in situ Annexin V staining, controlled by non-transfected T-cells and T-cells transfected by a contol vector. Results: A FAS-induced tumour counterattack of SW620-colon carcinoma cells against Jurkat-T-cells after coincubation was confirmed in vitro. The positive transfection rate of the FLIP-transfected T-cells was 32 %. The apoptosis rate of the transfected T-cells decreased significantly after coincubation in comparison to the respective control groups. Conclusions: Our results show that a tumour counterattack against activated T-cells can be reduced by c-FLIP-transfection of the Jurkat-T-cells by a targeted deactivation of the AICD cascade. This regain of the immune competence of activated T-cells against the tumour cells may constitute a new and promising strategy of systematic tumour therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Nagata S, Goldstein P (1995) The Fas death factor. Science 267: 1449–1456
Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas-Ligand, a novel member of the tumor necrosis family. Cell 75: 1169–1178
O’Connel J, O’Sullivan G, Collins JK, Shanahan F (1996) The Fas Counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas Ligand. J Exp Med 184: 1075–1082
Wimmenauer S, Steiert A, Wolff-Vorbeck G, Xing B, Baier PK, Rückauer KD, Kirste G, von Kleist S (1999) Influence of cytokines on the expression of fas ligand and CD44 splice variants in colon carcinoma cells. Tumor Biol 20: 294–303
Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer J-L, Schröter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386,3: 517–521
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this paper
Cite this paper
Steiert, A. et al. (2007). Eliminierung des Tumorcounterattack von Kolonkarzinomzellen über gentechnische Suppression der FAS vermittelten Apoptose durch FLIP-Überexpression in humanen T-Zellen. In: Steinau, H.U., Schackert, H.K., Bauer, H. (eds) Chirurgisches Forum 2007. Deutsche Gesellschaft für Chirurgie, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71123-0_13
Download citation
DOI: https://doi.org/10.1007/978-3-540-71123-0_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-71122-3
Online ISBN: 978-3-540-71123-0
eBook Packages: Medicine (German Language)